Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody plus chidamide-based induction followed by PD-1 antibody plus pegaspargase and pemetrexed consolidation for relapsed or refractory peripheral T-cell lymphoma
ChiCTR2100046858Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, prednisone, etoposide, lenalidomide, pegaspargase and 1 more in peripheral T-cell lymphoma (PTCL), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
tucidinostatprednisoneetoposidelenalidomidepegaspargase
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2100046858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046858.